* Vaxart Inc VXRT.OQ VXRT.O is expected to show a rise
in
quarterly revenue when it reports results on May 2 (estimated)
for the period ending March 31 2024
* The South San Francisco California-based company is
expected to
report a 18.5% increase in revenue to $800 thousand from $675
thousand a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Vaxart Inc is for a loss
of 14
cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 12.1%
in the last three months.
* Wall Street's median 12-month price target for Vaxart Inc
is
$5.00, above its last closing price of $0.71.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.16 -0.14 -0.12 Beat 17.2
Sep. 30 2023 -0.18 -0.18 -0.11 Beat 37.7
Jun. 30 2023 -0.18 -0.18 -0.16 Beat 11.1
Mar. 31 2023 -0.18 -0.19 -0.19 Met -1.8
Dec. -0.22 -0.23 -0.18 Beat 20.9
31 2022
Sep. 30 2022 -0.25 -0.24 -0.23 Beat 5.2
Jun. 30 2022 -0.22 -0.21 -0.23 Missed -9.5
Mar. 31 2022 -0.16 -0.16 -0.20 Missed -23.1
This summary was machine generated April 30 at 11:42 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)